Are there major competitors to Eli Lilly's new drug?

Yes, the main competitor is Novo Nordisk with its Wegovy and Ozempic drugs, along with other companies.

Eli Lilly Plans to Seek Approval for New Obesity Drug in 2027

Q: What was the average weight loss achieved by the drug in clinical trials?

The drug achieved an average 28% weight loss over 80 weeks at the highest doses tested.

Eli Lilly announced Thursday it is on track to seek FDA approval for its next-generation obesity drug in early 2027. Late-stage trials showed an average 28% weight loss over 80 weeks at the highest doses.

By: Wrqti Editorial

July 23, 2026

2 min read

Source: Barrons.com

Key Numbers

weight loss percentage

28%

trial duration weeks

Eli Lilly (LLY) announced Thursday that it is on track to file for FDA approval of its next-generation obesity drug in early 2027. The company became the first drugmaker to reach a trillion-dollar valuation last fall, driven by soaring sales of its weight-loss drugs.

The Product

The new drug is a weekly injectable targeting adults with general obesity. In late-stage trials, it reduced participants' weight by an average of 28% over 80 weeks at the highest doses tested.

Pricing and Availability

Lilly has not yet disclosed pricing or insurance coverage details for the new drug. The approval filing is expected in 2027, meaning commercial launch could occur in 2028 or 2029 if approved.

Competition

Lilly faces strong competition from Novo Nordisk (NVO), maker of Wegovy and Ozempic, and other companies developing obesity treatments. Success of the new drug could solidify Lilly's position in the growing obesity market.

Potential Impact on the Company

If approved, the drug could significantly boost Lilly's revenue, especially as the obesity drug market is projected to exceed $100 billion by 2030. However, regulatory and competitive risks remain.

Frequently Asked Questions

Eli Lilly plans to file for FDA approval in early 2027.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.